

For Release: Wednesday January 6, 2010

Contact: Dr. Laura Strong, President and Chief Operating Officer, 608-441-2950

Quintessence Biosciences to Present at OneMedForum 2010

SAN FRANCISCO, CA AND MADISON, WI –Quintessence Biosciences, Inc. announced today that Laura Strong, President and COO, will present at the OneMedForum 2010 on Wednesday January 13, 2010 at 3 pm Pacific Time. The presentation will include an update on the pipeline of EVade™ Ribonuclease products, including QBI-139, which is in a Phase I oncology trial.

About Quintessence Biosciences, Inc.

Quintessence Biosciences, Inc. is a private biopharmaceutical company focused on development of proprietary cancer therapies based on the EVade™ Ribonuclease technology. Quintessence's first product candidate, QBI- 139, is in a Phase 1 clinical trial. The company also has a pipeline of other EVade™ Ribonuclease products in preclinical research. For more information, visit www.quintbio.com.

About QBI-139

QBI-139 is a potent anticancer agent based on the EVade™ Ribonuclease technology. The technology provides an opportunity to attack RNA, an exciting new drug target, in cancer cells with analogs of the human pancreatic ribonuclease 1. In preclinical disease models, QBI-139 has shown a strong tolerability profile and outstanding tumor growth inhibition *in vivo* against human colorectal, pancreatic, non-small cell lung, prostate, and ovarian solid tumors. QBI-139 is currently in a solid tumors Phase I human clinical trial.

About the OneMedForum 2010

Held Annually in San Francisco, the OneMedPlace Finance Forum was created to connect emerging healthcare and life science companies with investors and strategic partners. Over 100 company presentation will occur by some of the most promising - and typically least recognized - companies in the world. All content will be captured and available at OneMedPlace.com. The third annual conference will take place at the Sir Francis Drake Hotel in San Francisco January 12 -13, 2010.